FDx Advisors Inc. grew its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 29.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,774 shares of the biopharmaceutical company’s stock after purchasing an additional 1,299 shares during the quarter. FDx Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,157,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Whittier Trust Co. increased its position in Regeneron Pharmaceuticals by 195.7% during the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 45 shares during the period. Rehmann Capital Advisory Group increased its position in Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 68 shares during the period. Intercontinental Wealth Advisors LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $33,000. Blume Capital Management Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Finally, We Are One Seven LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $87,000. 66.52% of the stock is currently owned by institutional investors.
In other news, Director Joseph L. Goldstein sold 1,791 shares of the firm’s stock in a transaction that occurred on Thursday, January 10th. The shares were sold at an average price of $410.00, for a total value of $734,310.00. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $5,786,740. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Christopher R. Fenimore sold 1,848 shares of the firm’s stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $358.97, for a total transaction of $663,376.56. Following the completion of the sale, the vice president now owns 9,871 shares in the company, valued at $3,543,392.87. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,645 shares of company stock worth $1,399,980. Insiders own 12.42% of the company’s stock.
REGN stock opened at $418.62 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. Regeneron Pharmaceuticals Inc has a 12 month low of $281.89 and a 12 month high of $431.32. The stock has a market capitalization of $45.96 billion, a price-to-earnings ratio of 21.14, a PEG ratio of 1.67 and a beta of 1.27.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, beating the consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. During the same period last year, the firm earned $5.23 EPS. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current fiscal year.
REGN has been the topic of a number of recent research reports. TheStreet raised shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, January 17th. Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price target on the stock in a research report on Friday, January 4th. Cowen reaffirmed a “hold” rating and set a $385.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, January 7th. Goldman Sachs Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “conviction-buy” rating in a research report on Thursday, December 13th. Finally, Oppenheimer set a $440.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, December 2nd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $408.82.
WARNING: This piece of content was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://zolmax.com/investing/regeneron-pharmaceuticals-inc-regn-shares-bought-by-fdx-advisors-inc/2918752.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Return on Equity (ROE)
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.